Skip to main content

Branded

  • Hamacher Resource Group to deliver presentation on optimal diabetes marketing

    WAUKESHA, Wis. — Hamacher Resource Group on Tuesday announced it will present “Marketing Diabetes in the Retail Setting” June 21 at the Marketing Diabetes Prevention and Awareness Conference in Atlanta.

    Dave Wendland, VP and part of the owners group at HRG, will share ideas about how retail pharmacies can collaborate with suppliers to bring innovation to the diabetes care category to better serve patients, capture incremental sales and significantly grow the category’s reach.

  • AstraZeneca, Rigel partner on worldwide license agreement for chronic asthma treatment

    SOUTH SAN FRANCISCO, Calif. — AstraZeneca and Rigel Pharmaceuticals have entered an exclusive worldwide license agreement for the global development and commercialization of an investigational treatment for moderate to severe chronic asthma.

  • Sanofi, Joslin Diabetes Center enter collaboration

    PARIS — A drug maker and a teaching and research affiliate of Harvard Medical School announced a new collaboration to promote the development of new medicines for the treatment of diabetes and related disorders.

  • Pfizer: Phase-3 study of Xalkori met primary endpoint

    NEW YORK — Pfizer announced the results of its late-stage clinical trial of Xalkori (crizotinib).

    The drug maker confirmed that its Profile 1007 study met its primary endpoint, demonstrating that the drug significantly improved progression-free survival in previously treated patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer, compared with those treated with pemetrexed or docetaxel. The study also marked the first randomized phase-3 study in ALK-positive advanced NSCLC patients, Pfizer said.

  • Takeda: Edarbyclor demonstrates statistically superior blood-pressure reductions

    DEERFIELD, Ill. — A Takeda drug designed to treat hypertension was statistically superior to a competing drug in reducing systolic blood pressure among patients in a late-stage clinical trial.

  • FDA declines to approve Pfizer's tafamidis meglumine

    NEW YORK — The Food and Drug Administration has declined to approve a drug designed to treat a rare, progressive and fatal neurodegenerative disease.

    The FDA issued a complete response letter to Pfizer pertaining to the company's new drug application for tafamidis meglumine, requesting the completion of a second efficacy study to establish substantial evidence of effectiveness prior to an approval. The agency also has asked for additional information on the data within the current tafamidis NDA.

  • Maxim Health, Citi partner on flu shot payment card

    NEW YORK — Maxim Health Systems now is a certified distributor of the Citi Flu Care card, the healthcare group announced Tuesday.

  • Court rules against Merck in Nasonex patent case

    WHITEHOUSE STATION, N.J. — Merck announced that the U.S. District Court for the District of New Jersey ruled against the company in a patent infringement suit against Canada-based drug maker Apotex.

X
This ad will auto-close in 10 seconds